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Abstract 
Background 
Deceased organ donors are routinely screened for behaviours that increase the risk of 
transmissible blood borne viral (BBV) infection, but the impact of this information on 
organ donation and transplant outcome is not well documented. Our aim was to 
establish the impact of such behaviour on organ donation and utilization, as well 
transplant recipient outcomes. 
Methods 
We identified all UK deceased organ donors from 2003-2015 with a disclosed history 
of increased risk behaviour (IRB) including intravenous drug use (IVDU), 
imprisonment and increased risk sexual behaviour.  
Results 
Of 17,262 potential donors, 659 (3.8%) had IRB for BBV and 285 (1.7%) were 
seropositive for BBV, of whom half had a history of IRB (mostly IVDU (78.5%)). Of 
actual donors with IRB, 393 were seronegative for viral markers at time of donation. 
A history of recent IVDU was associated with fewer potential donors proceeding to 
become actual organ donors (64% vs. 75%, p=0.007). Donors with IRB provided 
1,091 organs for transplantation (624 kidneys and 467 other organs). Transplant 
outcome was similar in recipients of organs from donors with and without IRB. There 
were three cases of unexpected HCV transmission, all from an active IVDU donor 
who was HCV seronegative at time of donation, but was found to be viraemic on 
retrospective testing 
Conclusion 
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Donors with a history of IRB provide a valuable source of organs for transplantation 
with good transplant outcomes and there is scope for increasing the use of organs 
from such donors. 
 
Introduction 
Unintended transmission of Hepatitis C (HCV), Hepatitis B (HBV), Human 
Immunodeficiency Virus (HIV) and Human T-lymphotrophic virus (HTLV) from 
deceased organ donors is a rare but serious complication of organ transplantation (1). 
This risk is minimised by performing relevant laboratory screening investigations in 
deceased donors prior to implantation of their organs. Currently available screening 
strategies cannot completely discount the presence of a recently acquired viral 
infection, and considerable importance is attached to the identification of donors with 
a history of increased risk behaviour (IRB) associated with the acquisition of HCV, 
HIV, HBV and HTLV(1-4). While the discard of organs from those with a history of 
IRB would minimize disease transmission, it would markedly reduce the number of 
transplants performed. Consequently the risk of disease transmission from donors 
with IRB needs to be balanced against the potential benefits of organ transplantation. 
Solid organ donors who have a history of prior or current intravenous drug use 
(IVDU), or of recent or historical imprisonment, and those who have a history of 
high-risk sexual behaviour are viewed at greatest risk of transmission of BBV (2,3). 
In the United Kingdom (UK), current guidance from the Advisory Committee for the 
Safety of Blood, Tissues and Organs and the European Directive on Organ Donation 
requires that detailed information on ‘behavioural history that could have put the 
donor at an increased risk of blood borne viruses’ be obtained (5). The information 
needed includes ‘questions about risk behaviours such as recreational drug use, men 
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who have sex with men (MSM), and risks such as accidental body fluid exposure’ (5). 
UK guidance on donor assessment is consistent with that in the United States where 
the need to assess behavioural risk factors for a donor to be at increased risk of 
transmitting HIV, HBV and HCV is highlighted (2). The donor history with respect to 
such IRB also provides an important context for the interpretation of the results from 
microbiological screening for HIV, HCV, HBV and HTLV (3,5,6). Current screening 
tests for viral markers have limited sensitivity, and serological screening may result in 
an infective window period of up to 70 days following infection when antibodies to 
virus are undetectable (6). 
We report the UK experience of deceased organ donors, both potential and actual, 
with a history of IRB, highlighting the overall prevalence and types of IRB. Our aim 
was to establish the impact of IRB on organ donation and utilization, as well as on 
their transplant recipient outcomes. 
 
Methods 
Identification of deceased organs donors with increased-risk behaviour 
The UK Transplant Registry was examined to identify all deceased organ donors 
between 1st January 2003 and 31st December 2015, who had a history of any one of 
the following IRB: IVDU, current or previous imprisonment, MSM, sex in exchange 
for money or drugs, and high risk sexual partner (defined as a sexual relationship with 
any of the previously mentioned increased risk groups). For the purposes of this 
study, “potential donors” were defined as deceased donors for whom consent/ 
authorization for organ donation had been obtained, “actual organ donors” as 
deceased donors who had one or more solid organs removed for transplantation on the 
basis that recipient centres had provisionally agreed to use them for transplantation, 
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and “utilised organ donors” as actual organ donors whose organs where eventually 
transplanted. The decision as to whether or not a potential donor proceeds to organ 
donation is dependent on transplant clinicians at individual transplant centres 
indicating that they are willing to accept the organs for transplantation. There are no 
centralized clinical advisors involved in this decision.  
 In the UK, a donor transplant coordinator (designated in 2008 as a Specialist Nurse in 
Organ Donation) is required to enquire from the next of kin, medical notes and the 
potential donors family doctor, whether there is a history of IRB and record these 
findings. Additional UK guidance published in 2000 highlighted the requirement to 
screen potential organ donors for behavior associated with BBV.  
Free text entries of all potential donors were searched using the terms ‘intravenous 
drug use’ ‘sex worker’ ‘Men who have sex with men’ and ‘prison’. All common 
abbreviations, misspellings, synonymous terms and colloquialisms of the above 
search terms were also searched. Donors with a history of IVDU and imprisonment 
were sub-categorised based on whether or not they had been an IVDU or imprisoned 
during the preceding 12 months. Donors with a history of high-risk sexual behaviour  
were sub-categorised according to the type behaviour into any one of ‘high risk 
partner’, ‘sex worker’, and ‘prior high risk partner’.  
It is important to note that a number of patients did not fall into the category of 
potential donors because formal consent for donation was not sought for a variety of 
reasons that included a belief by the clinicians caring for the patient that the patient’s 
IRB would exclude organ and tissue donation. Information on the number of patients 
that did not progress to become potential donors for the entire study period (2003-
2015) was not available but the potential donor audit (a prospective registry of all 
patients aged <80 years who died in critical care units of acute UK hospitals, 
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irrespective of their medical suitability to become organ donors) was interrogated to 
obtain information on patients excluded from the present analysis. Between January 
2009 and 31st December 2015 there were 12,040 potential donors analysed in the 
present study, and during the same period the Potential Donor Audit showed that 
1,022 patients with an identified IRB (89% IVDU) did not get consented for organ 
donation for a variety of reasons that included IRB. In 86 patients excluded from the 
present study, IVDU was stated explicitly as a reason why the patient’s family was 
not approached for consent for organ donation.  
 
Identification of recipients of organs from donors with increased-risk behavior 
 
The UK transplant registry was examined to identify recipients of organs from donors 
with IRB and information on outcome (patient and graft survival) obtained. UK 
transplant centres are required to notify NHSBT of any potential donor-derived 
disease transmission and adverse events relating to the donation process. This 
reporting requirement became mandatory when the new European Union Organ 
Donation Directive guidelines came into effect (2010) and was written into UK law in 
the Quality and Safety of Organs for Transplantation Regulations (2012).  Prior to 
2010, recipient centres were expected, according to UK guidance, to report any 
adverse outcomes in recipients relating directly to the organ donation process to 
NHSBT. Details of any donor transmitted infections were collected from a designated 
transplant incident reporting registry held by NHSBT.  
 
Statistical Analysis 
Univariate analysis comparing clinical characteristics between IRB and non-IRB 
potential donors, who were seronegative for BBV, was carried out using Student’s t-
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test for approximately normal continuous data, and the Mann-Whitney U test for non-
normal continuous data. Categorical comparisons were made using the χ2–squared 
test.  
Kaplan-Meier curves were used to show death-censored graft survival and patient 
survival and the univariate log-rank test was used to compare unadjusted survival 
rates.  
Cox proportional hazards regression model and a logistic regression model were fitted 
in a stepwise selection method in order to control for potentially confounding factors. 
Donor related variables considered for inclusion in the multivariate model were donor 
age, donor type, ethnic group, sex, past medical history of diabetes and hypertension, 
liver disease, cardiac disease, smoking history and whether the donor had a history of 
IRB. Recipient factors included were age, ethnicity, sex, primary renal disease, 
Human Leukocyte Antigen (HLA) mismatch level and cold ischaemic time.  
 All analyses were performed using Statistical Analysis System (SAS) (version 9.3) 
and p-values less than 0.05 were deemed to be statistically significant (7).  
 
HLA mismatch level (levels 1-4) was defined according to UK allocation policy for 
kidneys from brain-death donors and was based on the mismatch between donor and 
recipient (8). 
The United Kingdom Model for End-Stage Liver Disease score was used when 
assessing differences in liver recipient characteristics. This score is calculated based 
on the patient’s international normalized ratio, serum creatinine, serum bilirubin, and 
serum sodium (9,10).  
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Results 
One or more IRB was identified in 659 (3.8%) of potential deceased donors, and 454 
(3.6%) of actual organ donors. Of the potential donors with a history of IRB, 47% had 
a history of IVDU, 33% a history of imprisonment, 10% were MSM, and 9.9% a 
history of high risk sexual behaviour. For actual donors with a history of IRB, 41% 
had a history of IVDU, 37% had a history of imprisonment, and 21% had a history of 
high risk sexual behaviour, and these proportions did not differ significantly from the 
behaviours in potential donors (p=0.147).  
 
Organ donors who were seropositive for HIV, HCV, HBV and HTLV  
Overall, 285 (1.7%) of potential organ donors were found to be seropositive for BBVs 
markers.  
104 (36.5%) seropositive potential donors proceeded to organ donation; in contrast to 
the 78% conversion rate observed in seronegative potential donors (p<0.001). Organs 
from 81 (77.8%) of the seropositive organ donors were subsequently transplanted, 
compared to 95.7% of seronegative organ donors (p<0.001).  
Half (50.5%) of potential donors who were seropositive for viral infection had a 
history of IRB, and in most (78.5%) this included IVDU. A history of imprisonment, 
MSM and high risk sexual behavior was less common (16.7%, 2.7% and 2.1% 
respectively). The clinical characteristics of potential and actual seropositive donors 
are shown in table 1. Positive serology for HCV was more common in donors with a 
history of IRB. In contrast, markers of HIV, HBV and HTLV were all more common 
in seropositive donors with no history of IRB (table 1).  
The types of organs from seropositive organ donors that were used for transplantation 
differed according to whether or not there was a history of IRB. The 62 organ donors 
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with a history of IRB provided 48 livers and 11 kidneys that were used for 
transplantation, whereas the 42 donors with no history of IRB donated 25 livers and 
32 kidneys that were transplanted (p<0.001). 
 
Increased-risk behaviour and organ donation in donors who were seronegative for 
viral infection 
To examine the association between IRB and organ donation, all seropositive 
potential donors were excluded from subsequent analysis. After exclusion, there were 
16,977 remaining potential donors of which 12,737 (75%) proceeded to organ 
donation (figure 1). A history of IRB was identified in 515 (3%) of potential and 392 
(3%) of actual organ donors, suggesting that overall, a history of IRB did not 
adversely influence the decision to proceed to organ donation. 25% of potential 
donors with no history of IRB and 24% of those with a history of IRB did not proceed 
to donation (p=NS). Potential donors with a history of IRB were, when compared to 
those with no history of IRB, much younger, and significantly less likely to have 
hypertension, cardiac disease and diabetes (table 2). Potential donors with IRB were, 
however, more likely to be smokers and to have a history of alcohol abuse. 
There were significant differences in the conversion rate from potential to actual 
donors according to the type of IRB (figure 2). Potential donors with a history of 
IVDU were less likely to proceed to organ donation than donors with no history of 
IRB and this effect was most marked in potential donors with a history of recent 
rather than historical IVDU Those with a history high risk sexual behaviour alone 
were as likely to proceed to donation as those with no history of high risk sexual 
behaviour (figure 2). History of imprisonment (previous or current) alone was 
associated with an increased rate of proceeding to donation compared to donors with 
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no history of IRB (figure 2).  However, when a logistic regression model was fitted to 
adjust for the significant differences in age and co-morbidity between donors with or 
without a history of IRB, IRB was associated with significantly fewer potential organ 
donors becoming actual organ donors (odds ratio=1.580 (95% CI 1.273-
1.962,p<0.001).When the logistic regression model was fitted for the different types 
of IRB, IVDU (both recent and historical) was associated with significantly fewer 
potential organ donors becoming actual organ donors (odds ratio=3.552 (95% CI 
(2.373-5.315), p<0.001 and odds ratio =1.984 (95% CI 1.205-3.268) p=0.007, 
respectively )(table 3). 
 
The number of potential donors with a history of IRB increased markedly over the 13-
year study period and the percentage of donors proceeding to donation also rose in the 
latter part of the study period (figure 3).   
 
Clinical characteristics of actual  organ donors with history increased-risk 
behaviours 
Potential donors with a history of IRB, that proceeded to become actual organ donors 
were younger (39.8 ± 12.6 years vs. 44.3 ± 11.6 years, p<0.001) and more likely to be 
DBD than DCD donors (36.2% DCD vs. 82.9% DCD, p<0.001) than those potential 
donors with IRB who did not proceed to organ donation. 
The clinical characteristics of the 392 actual organ donors with a history of IRB, 
along with the clinical characteristics of all other deceased organ donors are shown in 
table 3. Actual organ donors with a history of IRB were younger, more often males 
and more likely to be of an ethnic minority other than white. Organ donors with a 
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history of IRB were more likely to have a history of smoking and of alcohol abuse 
(table 4). 
 
Clinical characteristics of recipients receiving organs from donors with increased-
risk behaviour 
Over the 13-year study period, a total 1,091 transplants were carried out using organs 
from seronegative deceased donors with a history of IRB (624 kidney, 278 liver, 63 
heart, 39 lung (including one lung pair), 2 heart and lung transplants, 84 pancreases, 
and 1 bowel transplant).  
Recipients of kidneys from donors with a history of IRB were younger, more often of 
non-white ethnicity and less well matched for HLA than recipients of kidneys from 
donors with no IRB (table 5). Recipients of kidneys from donors with IRB spent a 
similar amount of time on the transplant waiting list and had a similar duration of 
dialysis pre-transplant when compared to those who received kidneys from donors 
without IRB. Recipients of kidneys from donors with IRB had similar graft and 
patient survival to those who received kidneys from all other deceased donors (figure 
4a). When the recipients of the different types of IRB were compared to all other 
recipients, a donor history of recent IVDU did not adversely influence patient or graft 
survival (figure 4b). 
Recipients of livers from donors with a history of IRB were older, more often male, 
had a lower UKELD score, and more often HCV positive than recipients of livers 
from donors with no IRB (Table 6). Similarly, patient and graft survival following 
liver transplantation was comparable for recipients of livers from donors with and 
without IRB (figure 5a and figure 5b).  
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Because of the differences in donor and recipient demographics between recipients 
that received organs from donors with a history of IRB compared to those that did 
not, a Cox proportional hazards regression model was fitted to adjust for donor and 
recipient age, donor history of hypertension, HLA mismatch, cold ischaemic time and 
primary recipient disease. This showed that patient survival after kidney 
transplantation was not adversely affected by a donor history of IRB (supplementary 
table 1). After assessing whether the different sub-types of IRB adversely impacted on 
transplant outcome the multivariate analysis indicated recipients of kidneys from 
donor’s with high-risk sexual behaviour had significantly worse patient survival than 
those who received kidneys from donors with no history of high-risk sexual 
behaviour, even after adjusting for donor and recipient factors. Each of the high-risk 
sexual behaviours was assessed in turn, and this revealed that it was only those who 
received kidneys from donors with a high-risk sexual partner that had worse patient 
survival. 
 
Disease transmission 
From the 1,091 organ transplants from donors with IRB, one liver recipient and two 
renal recipients (all from the same organ donor) developed donor-derived HCV 
infection.  The donor of the organs had a history of recent IVDU, and tested negative 
for HCV antibody at time of donation. Retrospective testing of the donor serum 
obtained at donation was positive for HCV Ribonucleic Acid. The liver recipient was 
known to be HCV positive at time of transplantation, but it was noted that the 
predominant HCV genotype changed from genotype 1 pre-transplant to donor 
genotype 3 after transplant. The two renal recipients were both HCV negative prior to 
transplantation. 
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 There were no reported unexpected HIV, HBV or HTLV transmissions from these 
IRB donors. 
 
Discussion 
Routine screening of all potential organ donors for a history of IRB to determine risk 
of transmission of BBV infection is routinely undertaken in most countries to help 
inform the decision on organ usage. The present analysis provides insight on the 
impact of this policy on organ donation and utilization in the UK, where the 
prevalence of blood borne viral infection is slightly lower than that in the USA and 
broadly similar to Western Europe (11-14).  
Around 4% of all potential organ donors, for whom consent for donation was 
obtained, had a history of IRB and 22% of these (2% of all potential donors) were 
seropositive for blood borne viral infection (mostly HCV), at the time organ donation 
was being considered and over half had a history of IRB. Positive serology for blood 
borne viruses may indicate a very high risk of disease transmission during 
transplantation, and enables an informed decision on whether to proceed with organ 
donation, and if so, to allocate organs to appropriate potential recipients; in the 
majority of cases the recipients are likely to be selected on the basis that they already 
have infection corresponding to that identified in the donor.  
In the present study, we were particularly interested in the extent to which IRB in 
seronegative potential donors impacted on organ donation and transplantation   
Overall, around three quarters of all potential organ donors in the UK proceeded to 
become actual organ donors, on the basis that transplant implanting centres had 
provisionally accepted them for transplantation. A history of IRB (all types) was not 
associated with a reduction in the proportion of potential donors that proceeded to 
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become organ donors. However, a history of IVDU accounted for nearly half of all 
IRB and was associated with a relatively small but significant reduction in the 
proportion of potential donors proceeding to donation, especially when the drug use 
may have been recent.   
Potential donors with IRB were significantly younger and had less additional 
comorbidity than those with no IRB, and when these variables were taken into 
account by logistic regression analysis, IVDU (both recent and historical) were 
associated with donors not proceeding to become actual organ donors. Our analysis of 
the potential donor audit (a prospective registry of all patients aged <80 years who 
died in critical care units of acute UK hospitals, irrespective of their medical 
suitability to become organ donors) indicated that a large number of these identified 
registry patients did not get consented for organ donation because of their history of 
IRB (in particular IVDU).  
The number of potential donors with IRB in the present study increased markedly 
over the 13-year study period. This likely reflects, for the most part, a true increase in 
the number of such donors over time, in line with the general trend towards increased 
consideration of organs from other types of high-risk donor (15). However, it is also 
likely that some of the increase in potential donors with IRB over time may be 
attributable to a bias in data capture, as clinical practice in organ donor screening by 
transplant coordinators and documentation became more standardised.  
While the risk of disease transmission in seronegative donors with IRB is very low, 
not all transplant centres routinely assess recipients for graft-derived acquisition of 
blood borne viral disease and consequently the present study may provide and 
underestimate of disease transmission from donors with IRB. Although seronegative 
donors with a history of IRB represent a small proportion of the total donor 
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population they made a significant contribution to organ transplantation in the UK 
over the 13-year study period, providing organs for over a thousand transplants.  
There were three confirmed transmissions of HCV to two renal transplant recipients 
and one liver transplant recipient. All three episodes of disease transmission 
originated from the same donor, who was known to be an active IVDU at time of 
donation. Using standard serological testing the window period from infection with 
HCV to detection by antibody assays is around 70 days (6,16-18) and with Nucleic 
Acid Technology (NAT) is 3-5 days (6,16,18). However, both serological testing and 
NAT testing carries the risk of false positive results and hence the unnecessary 
discard of potentially infection free organs from potential donors. NAT testing is only 
currently available in selected UK centres and recent evidence suggests that NAT 
testing would improve utilization of organs from IRB donors, but not from donors 
with no history of IRB (6). Hence even when NAT testing is available a thorough 
history regarding IRB is still important to aide interpretation of positive results.  
As might be expected, recipients of organs from seronegative donors with IRB had 
transplant outcomes (patient and graft survival) comparable to recipients of organs 
from deceased donors with no history of IRB, even after adjustment for differences in 
donor and recipient demographics. However, those who received kidneys from donors 
with a high-risk sexual partners had worse patient survival than all other deceased 
donors. The exact cause of this remains unclear. When the causes of renal recipient 
death in this cohort were examined, no deaths (n=8) were on inspection attributable to 
disease transmission from the donor (n=1 Gastro-intestinal haemorrhage, n=1 
haemorrhage from graft site, n=1 septicaemia, n=1 liver viral hepatitis, n= 2 post-
transplant lymphoproliferative disorder, n= 1 non-lymphoid malignant disease, n=1 
ischaemic heart disease). The case of viral hepatitis was fulminant liver failure 
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secondary to HCV genotype 1b, which was already present in the recipient prior to 
transplantation. There was no significant difference in graft or patient survival in 
recipients of livers from donors with high-risk sexual behavior and all other deceased 
donors.  
The comparison of recipient characteristics according to whether or not they received 
a kidney from a donor with a history of IRB revealed that recipients of kidneys from 
donors with IRB were significantly younger and significantly more likely to be of 
non-white ethnicity. Donors with a history of IRB were also significantly younger and 
of non-white ethnicity than all other deceased donors, and kidney allocation and 
acceptance policies in terms of age, blood group and HLA matching would likely 
explain the differences observed in recipient demographics. In support, it was notable 
that for liver transplant recipients, where HLA-matching is not undertaken there was 
no significant difference in the ethnicity of recipients according to whether or not they 
received a liver from a donor with IRB. Because kidney donors with IRB were 
significantly younger than other deceased kidney donors, and recipients of kidneys 
from younger donors have improved transplant outcomes, it might have been 
expected that transplant outcomes would have been better in recipients of kidneys 
from donors with IRB (15, 19). The number of recipients of kidneys from donors with 
IRB in the present study may not have been sufficient to demonstrate the advantage of 
younger donor age on transplant outcome. 
The present study is the first to report in detail on different categories of IRB in a 
national cohort of deceased organ donors, and provides important information on 
which to base future transplant policy for managing the risk of disease transmission. 
The numbers presented likely represent an underestimate of potential donors with IRB 
in the donor population, because of underreporting. This is evidenced by the small 
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number of reported MSM in the registry (0.44%), whilst estimates from a recent US 
census analysis and meta-analysis estimated that around 3.9% of the US adult male 
populations are MSM, and in the UK it is estimated that 2.0-2.5% of the adult male 
population are MSM (20,21).  
Research suggests that a patient would be willing to accept a kidney from a donor 
with IRB if the organ was deemed otherwise healthy (22): individuals are more 
concerned about the perceived poor quality of the organ and the risk of disease 
transmission rather than having a prejudice or concern about a particular type of 
increased risk behaviour per se (22). 
While the present study indicates that a history of IRB, particularly IVDU, in 
seronegative potential donors is associated with a reduction in organs being accepted 
for transplantation, such donors represent a valuable source of organs for 
transplantation and the risk of disease transmission in the context of UK blood borne 
virus epidemiology is relatively small. Moreover, recent advances in the management 
of transmissible viruses particularly HCV, means that even if viral disease 
transmission occurs it can in many cases be successfully managed (23). It has also 
been suggested that kidneys from seronegative donors with a history of IRB may be a 
valuable source of organs for potential recipients with an increased likelihood of 
death whilst on the waiting list (24-26).  When organs from donors with a history of 
IRB are used for transplantation it would be prudent for all centres to test recipients 
within an appropriate time period following transplantation in order to exclude donor 
derived infection. 
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Conclusions 
Around 4% of UK deceased donors have an identifiable history of behaviour 
associated with an increased risk of blood borne transmissible viral infection, but are 
seronegative at time of donation. Three quarters of such donors provide organs for 
transplantation with good transplant outcomes, and apparently low risk of disease 
transmission. Recent advances in the treatment of viral disease, particularly HCV, 
further reduce the risks associated with disease transmission. Donors with a history of 
IRB provide a valuable source of organs for transplantation with good transplant 
outcomes and there is scope for increasing the use of organs from donors with IRB, in 
particular for donors with a history of IVDU. 
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Figure 1. Flow diagram for seronegative organ donors identified with increased-risk 
behaviour 
 
Figure 2. Proceeding and non-proceeding seronegatiove consented organ donors 
according to whether or not they had history increased-risk behaviour. 
IVDU=Intravenous drug use; IRB= Increased Risk Behaviour 
* All p values refer to category of increased risk behaviour compared to all donors 
with no history of increased risk behaviour. 
 
Figure 3. Number of seronagtive potential donors with increased-risk behaviour 
whose organs were used for transplantation and those whose were not used for 
transplantation.  
Proportion of potential organ donors with a history of high-risk behaviour who did not 
proceed to organ donation is shown above each colum.  
 
Figure 4a and Figure 4b. Patient and Graft survival of kidney transplant recipients 
from organ donors with a history of increased risk behaviour and from all other 
deceased organ donors 
Figure 5a and Figure 5b. Patient and Graft survival of liver transplant recipients from 
organ donors with increased-risk behaviour and all other deceased organ donors  
 
 
